MedTrace Logo

Biweekly Docetaxel in Patients With Metastatic Breast Cancer.

NCT02041351 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2016-01-27

No results posted yet for this study

Summary

There is clinical benefit of docetaxel administered to patients who have progressed to 3 or more lines of chemotherapy including prior exposure to paclitaxel or docetaxel; using docetaxel in metastatic stage breast cancer previously exposed to taxanes equal therapeutic responses are obtained that it never received taxanes.

Conditions

Interventions

DRUG

Docetaxel

evaluate the activity of docetaxel on, metastatic lesions when measured after 4 cycles of chemotherapy

Sponsors & Collaborators

  • Centro Universitario contra el Cáncer

    lead OTHER

Principal Investigators

  • Jesús L Santos, doctor · Centro Universitario contra el Cáncer U.A.N.L.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-01-31
Completion
2015-12-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02041351 on ClinicalTrials.gov